Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Share News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.80
Bid: 3.70
Ask: 3.90
Change: 0.00 (0.00%)
Spread: 0.20 (5.405%)
Open: 3.80
High: 3.80
Low: 3.80
Prev. Close: 3.80
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Tan Delta revenue jumps; Kendrick Resources loss widens

Fri, 29th Sep 2023 21:19

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

Tan Delta Systems PLC - Sheffield, England-based equipment monitoring and data analysis sensors maker - Reports revenue in the six months to June 30 increased by 54% to GBP0.96 million from GBP0.62 million the year prior. Pretax loss totalled GBP298,000 compared to pretax profit of GBP21,000. Basic and diluted loss per share was GBP0.01 against zero last year. Says revenue was primarily driven by a small number of prospects who commenced implementations following their evaluation period, and by a number of small sales to new customers commencing their evaluations. In the second half, expects more customers to enter and commence implementation on their equipment fleets, as well as contribution from our off the shelf SENSE-2 and MOT products.

----------

Oriole Resources PLC - London-based gold exploration company, focused on an early stage exploration project in Cameroon and Senala gold project in Senegal - Reports zero revenue in the six months to June 30, unchanged from the year prior. Administration expenses fell to GBP523,000 from GBP583,000 but pretax loss widened to GBP863,000 from GBP392,000. This reflected an adverse, non-cash foreign exchange loss on overseas assets. Basic loss per share totalled GBP0.03 versus zero the year before.

----------

CAP-XX Ltd - Sydney-based supercapacitor and energy management system manufacturer - Reports revenue in the year to June 30 of AUD3.6 million, down from AUD5.6 million the year prior. Pretax loss widened to GBP5.6 million from GBP4.9 million the year before and basic loss per share totalled 1.1 cents compared to 1.0c. Continues to pursue patent infringement action against Maxwell Technologies and other parties. Notes operating expenses were negatively impacted by AUD1.5 million of associated legal expenditure, down AUD1.0 million on prior year.

----------

Fusion Antibodies PLC - Belfast-based contract research organisation providing discovery, design and optimisation services for therapeutic antibodies to the healthcare market - Reports revenue in the year to March 31 fell 40% to GBP2.9 million from GBP4.8 million the year before, while the pretax loss widened to GBP2.9 million from GBP1.3 million. Basic loss per share totalled 10.0 pence compared to 4.6p. Explains this year has been a tough year and very commercially challenging. The year has seen a downturn in market conditions and investment into customers' early-stage therapeutic pipelines Venture capital funding, typically the primary source of investment for early-stage biotech, has fallen to its lowest level since 2019. Says: "Whilst there remains a significant amount of uncertainty over the timing and implementation of future contract wins due to reduced investment in the broader biotech sector, we expect trading to recover incrementally over the short to medium term both in respect of existing services and the new services coming on stream."

----------

Kendrick Resources PLC - London-based Scandinavia-focused mineral exploration and development company - Reports zero income in the six months to June 30 compared to GBP10,872 the year prior. Pretax loss widened to GBP244,534 from GBP184,700 while basic loss per share totalled 0.10 pence compared to 0.24p. Says review of the company's projects gives confidence that "our north European assets are well located with significant potential in the quickly emerging space of energy generation and storage." Remains confident they have assembled an enviable portfolio of projects and look forward to advancing all projects in the second half of the year and providing shareholders with the prospects of enhanced value flowing into next year.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
14 Jan 2022 14:15

Fusion Antibodies forms new scientific advisory panel

(Sharecast News) - Preclinical antibody discovery, engineering and supply company Fusion Antibodies announced the formation of a new scientific advisory panel (SAP) of experts on Friday, to support research and development across its range of antibody services, and to provide advice regarding emerging science and technology issues and trends.

Read more
6 Dec 2021 14:54

IN BRIEF: Fusion Antibodies loss widens on administrative expenses

IN BRIEF: Fusion Antibodies loss widens on administrative expenses

Read more
6 Dec 2021 11:59

Revenues rise, losses widen for Fusion Antibodies

(Sharecast News) - Contract preclinical antibody research provider Fusion Antibodies reported revenues of £2.4m in its first half on Monday, including a one-off milestone of £0.15m, which was up from £1.9m year-on-year.

Read more
2 Dec 2021 22:01

TRADING UPDATES: SRT Marine Systems and ULS Technology losses widen

TRADING UPDATES: SRT Marine Systems and ULS Technology losses widen

Read more
29 Nov 2021 16:08

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
7 Oct 2021 12:11

IN BRIEF: Fusion Antibodies signs USD1.8 million biotech contract

IN BRIEF: Fusion Antibodies signs USD1.8 million biotech contract

Read more
7 Oct 2021 11:59

Fusion Antibodies signs collaborative deal with US biotech firm

(Sharecast News) - Preclinical antibody discovery and supply company Fusion Antibodies has signed a collaborative research and development agreement with an unnamed US-based biotechnology company which was recently incorporated to focus on a number of innovative early-stage antibody programmes, it announced on Thursday.

Read more
24 Sep 2021 11:55

Fusion Antibodies performing in line in year-to-date

(Sharecast News) - Antibody discovery, engineering and supply company Fusion Antibodies said on Friday that revenue growth in the current year had been consistent year-on-year, and in line with its expectations.

Read more
24 Sep 2021 11:01

TRADING UPDATES: Iofina interim profit doubles on higher iodine sales

TRADING UPDATES: Iofina interim profit doubles on higher iodine sales

Read more
17 Sep 2021 16:08

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
24 Aug 2021 12:35

TRADING UPDATES: IG Design starts year well; Ilika in Stereax progress

TRADING UPDATES: IG Design starts year well; Ilika in Stereax progress

Read more
10 Aug 2021 14:01

IN BRIEF: Fusion Antibodies shares fall after annual loss widens

IN BRIEF: Fusion Antibodies shares fall after annual loss widens

Read more
10 Aug 2021 12:44

Revenues rise, losses widen for Fusion Antibodies

(Sharecast News) - Preclinical antibody discovery specialist Fusion Antibodies reported a 7% improvement in full-year revenues in its final results on Tuesday, to £4.2m.

Read more
23 Jul 2021 19:20

TRADING UPDATES: Parsley Box's new meal range; Macau Property NAV down

TRADING UPDATES: Parsley Box's new meal range; Macau Property NAV down

Read more
23 Jul 2021 09:32

Fusion Antibodies receives first research milestone payment

(Sharecast News) - Preclinical antibody discovery, engineering and supply company Fusion Antibodies has achieved its first research milestone payment as part of its ongoing collaboration with a major client, it announced on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.